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ABSTRACT
Introduction: The association between body mass index (BMI) and mortality in diabetes 
is complex and sparsely investigated for cardiovascular (CVD) outcomes. We aimed to 
investigate these relationships among patients with type 1 and type 2 diabetes using data 
from the Swedish national diabetes registry (NDR), with focus on potential reverse cau-
sality. Considering recent  ndings of marked excess risks among patients with early onset 
of type 1 diabetes we aimed to investigate risk factor trajectories based on age at onset.  
Methods: The thesis is based on data from the Swedish national diabetes registry (Study
I-IV) and matched controls taken from the general population (Study I and III), using 
statistical methods such as Cox regression, linear regression, mixed models and machine 
learning.  
Results: Study I, the short-term risk of death (<5 years from baseline) in patients with type 
2 diabetes was slightly lower among obese patients than in age- and sex matched controls, 
with a nadir among obese patients varying between 30-<40 kg/m2, depending on age. 
Long-term mortality (≥5 years from baseline) exhibited a stepwise increase from BMI 
25-<30 kg/m2, where patients with BMI ≥40 kg/m2 had a 2-fold risk of death compared to 
the general population, with similar  ndings for CVD death. In Study II, we found a slight 
increase in the risk of death, CVD death, major CVD (stroke or acute myocardial infarc-
tion [AMI]) and heart failure (HF) with rising BMI in patients with type 1 diabetes, but 
no increase in risk in patients with normal weight after exclusion of individuals with poor 
metabolic control, smokers and patients with follow-up shorter than 10 years. In Study III, 
the association between BMI and the risk of AMI was essentially  at but worsened with 
poor glycemic control, while, in contrast, there was a markedly increasing risk for HF 
with rising BMI with a nadir as low as ~18.5 kg/m2. The risk of HF was further exagger-
ated by poor glycemic control with an 8-fold excess risk of HF among patients with BMI 
≥40 kg/m2 and hemoglobin A1c (HbA1c) ≥70 mmol/mole. In Study IV, patients with an 
onset of type 1 diabetes ≤15 years had a high mean HbA1c of ~70 mmol/mole in early 
adulthood, whereas patients with a later onset (16-30 years) displayed a gradual increase 
in HbA1c up to a mean at ~65 mmol/mole, common for all groups regardless of age at on-
set. Machine learning models showed that baseline HbA1c (duration of diabetes >1 year) 
was linked to age, educational level and CVD risk factors.
Conclusions: Among patients with type 1 and type 2 diabetes our analyses provided no 
support for an obesity paradox for the outcomes of death (type 1 diabetes) and CVD com-
plications including HF after considering the in uence of reverse causality. The strong 
relationship between obesity and HF which was worsened by poor glycemic control, was 
absent for AMI, indicating different pathophysiological mechanisms behind these two 
outcomes. The age at onset of type 1 diabetes seems to be an important predictor of gly-
cemic control during the  rst years of adulthood, as well as for the prevalence of albumin-
uria leading to a more rapid decline in eGFR from an early age. Our study also stresses 
the importance of early optimization of CVD risk factors, in particular glycemic control, 
in patients with type 1 diabetes. 
Keywords: type 1 diabetes mellitus, type 2 diabetes mellitus, body mass index, cardiovas-
cular disease, epidemiology, reverse causality, mortality, heart failure, myocardial infarc-
tion, trajectories, machine learning
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This thesis is based on the following papers, referred to in the text by their Roman 
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Sambandet mellan body mass index (BMI) och mortalitet bland personer med diabe-
tes är komplex och inte så väl studerat för kardiovaskulära (CVD) utfall. Syftet med 
avhandlingen var att undersöka BMI och kardiovaskulära utfall inklusive hjärtsvikt 
(HF) bland personer med diabetes typ 1 och diabetes typ 2 med hjälp av data från na-
tionell diabetesregistret (NDR), genom att ta hänsyn till faktorer som är associerade 
med reverse causality. Med bakgrund av nyligen publicerad data som funnit en över-
risk för död, CVD och HF bland personer med diabetes typ 1, ville vi även undersöka 
utveckling över tid i riskfaktorer baserat på ålder vid insjuknande.  
Metodik
Avhandlingen bygger på data från NDR och kontroller från totalbefolkningsregistret 
med tillämpning av ett  ertal statistiska metoder som Coxregression, linjär regression, 
mixade modeller och machine learning. I Studie I och III jämfördes varje patient med 
5 kontroller från den generella befolkningen utan diabetes matchade för kön och ålder.
Resultat
Studie I. På kort sikt (<5år) var risken för död något lägre bland patienter med diabe-
tes typ 2 jämfört med ålders- och könsmatchade kontroller, och risken var lägst vid 
måttlig fetma (nadir vid BMI 30-<35 för död). På lång sikt däremot var kurvan linjärt 
stigande från BMI 25-<30 där de med mycket svår fetma uppvisade fördubblad risk 
för död jämfört med normalbefolkningen. 
Studie II. Vi fann en måttlig linjär riskökning mellan BMI och risk för död, major 
CVD och hjärtsvikt. Efter att vi uteslutit individer med låg grad av metabol kontroll, 
rökare och patienter med kort uppföljningstid, fann vi att patienter med diabetes typ 1 
och lågt BMI inte hade någon överrisk för något av utfallen. 
Studie III. Risken för att drabbas av HF jämfört med matchade kontroller steg linjärt 
med BMI och förvärrades med sämre metabol kontroll, och var upp till 8 ggr risken 
bland patienter med BMI ≥40 kg/m2 och HbA1c >70 mmol/mol. Risken för hjärtin-
farkt ökade med sämre metabol kontroll men påverkades inte nämnvärt av BMI. 
Studie IV. Patienter med tidig debutålder 0-15 år hade påtagligt höga HbA1c-värden 
omkring 70 mmol/mol vid 18-20 års ålder. Först i 35-40 års ålder planade värdena ut 
till omkring 65 mmol/mol. Patienter med debutålder 16-30 år hade ett lågt HbA1c 1 år 
efter debut kring target level 52 mmol/mol men nivåerna steg efter några år till ca 65 
mmol/mol. Machinelearningmodeller visade att ett högt baseline HbA1c (efter minst 
1 års diabetesduration) var associerat med låg ålder, albuminuri, högt eGFR, rökning, 
låg utbildning, förhöjt diastoliskt blodtryck och förhöjt LDL-kolesterol oavsett debut-
ålder och kön. 
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Slutsatser
Studie I-III. För patienter med diabetes typ 1 och diabetes typ 2 visade våra studier 
att det varken fanns någon obesitasparadox eller förhöjd risk bland normalviktiga 
patienter för varken död (diabetes typ 1), CVD-komplikationer (HF inkluderat),  efter 
att ha tagit hänsyn till reverse causality. Bland patienter med diabetes typ 2 fann vi ett 
starkt samband mellan fetma och HF, vilket inte var fallet med hjärtinfarkt, sannolikt 
beroende på två olika patofysiologiska mekanismer bakom dessa två utfall vilket in-
dikerar riktade medicinska insatser hos patienter med diabetes typ 2 för att undvika 
framtida HF. 
Studie IV. Debutålder spelar en viktig roll för den glykemiska kontrollen de första 
åren i vuxen ålder samt för förekomsten av albuminuri med stora skillnader fram till 
tidig medelålder, där patienter med låg debutålder företer en högre glykemisk belast-
ning och tecken på tidigare försämrad njurfunktion genom livet jämfört med patienter 
med senare debutålder. Vår studie pekade också på vikten av riskfaktorbehandling för 
alla patienter med diabetes typ 1 oavsett debutålder.
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Milestones of diabetes mellitus
One of the earliest known descriptions of symptoms resembling those of diabetes mel-
litus (Ebers papyrus) may be dated back to 1500 BC, where symptoms such as thirst 
and large quantities of urine were observed(1). A physician named Aretaios described 
a condition he called “diabetes” approximately 2,000 years ago, alluding to the exten-
sive volume of urine which one could not compensate for by drinking, which in the 
end led to death, however, if this was diabetes mellitus is not known, and the etiology 
was thought by some to be snakebite from the snake Dipsas (the thirst snake)(2). Cen-
turies later (17th century) Thomas Willis described “diabetes mellitus”, where “mel-
litus” referred to honey, while in the 19th century Richard Bright discovered that high 
volumes of urine were due to pancreas dysfunction(2). Paul Langerhans discovered 
the presence of the Langerhans islets in the pancreas, later to be identi ed to produce 
insulin by other researchers(2, 3). Even if there was progress in the understanding in the 
pathophysiology of diabetes, a major dilemma was the lack of effective treatment. 
For instance, cures are described based on different forms of diets in order to lower 
the intake of carbohydrates(4). Two main sides emerged, with patients recommended 
either forms of simple starvation or a high fat diet where “moderate” alcohol intake 
and opium drops were prescribed in order for patients to be able to endure the mo-
notonous diet, however, these rather unsuccessful diets would sooner or later lead to 
an inevitable death(5). 
Charles Best and Grant Banting who worked in the laboratory of John Macleod in 
Toronto became the  rst to extract and inject insulin, using dogs as test subjects, and 
with the help from James B. Collip they managed to re ne the process of insulin man-
ufacturing, hence, in 1922 the  rst human patient was injected successfully with exog-
enous insulin, with an immediate improvement of clinical symptoms(2). Macleod and 
Banting were jointly awarded the Nobel prize, although con icts had risen between 
the two pioneers, while Best was completely overlooked by the Nobel committee. 
Thus, in the end, neither Macleod nor Banting attended the ceremony in Stockholm, 
however, Banting split the award with Best and Macleod split the prize sum with Col-
lip(2).  Since the discovery of insulin in 1921, the treatment and care for patients with 
diabetes have been developed further in many ways(1-3). 
Dietary modi cations are still important, however, rather as a complementary treat-
ment in type 1 diabetes and type 2 diabetes alike(4), where strict regimens have been 
shown to lessen, or even result in remission of type 2 diabetes(6, 7). Modern treatment 
includes insulin pumps, continuous glucose monitoring (CGM) and closed loops(8), 
which have resulted in a substantial improvement in glycemic control in the past de-
cade(8). With very precise and re ned types of insulin(9), clinicians of today also have 
access to better treatment in type 2 diabetes with new analogues such as glucagon-like 
peptide-1 (GLP-1) receptor agonists and sodium-glucose transport protein-2 (SGLT-
2) inhibitors which are thought to lower the risk of late complications and to improve 
blood glucose control among patients with diabetes(10).    
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Current defi nitions of diabetes mellitus and it’s etiology
Diabetes is characterized by hyperglycemia which is the basic criterion for all types 
of diabetes, and the World Health Organization (WHO) has de ned diagnostic criteria 
to diagnose diabetes(3). There are currently two main classi cations of diabetes. Type 
1 diabetes, with a prevalence of about ~10% of the population with diabetes(3,11), is 
to a large degree an autoimmune disease, characterized by the destruction of ß-cells, 
whereas the remainder may have an unclear pathogenesis which may include patients 
classi ed with Maturity Onset Diabetes of Young (MODY)(12). Primary and second-
ary prevention of type 1 diabetes is currently not available since no intervention has 
been proven effective(13). There are several hypotheses regarding triggers of type 1 
diabetes relating to environmental factors such as psychological stress, diet related to 
diet de ciencies and high body weight which have been speculated to lead to ß-cell 
exhaustion and later ß-cell destruction due to autoimmunity(14). While the exact causes 
of type 1 diabetes are yet to be discovered, increasing dif culties have risen due to 
the increasing numbers of overweight and obese children, sometimes making it a 
challenge for clinicians to distinguish and classify diabetes in the young(15) although 
antibodies are an important biomarker of type 1 diabetes and may sometimes be pres-
ent in other forms of diabetes(16). 
The second type of diabetes is type 2 diabetes with a prevalence estimated to ~80-
90% of all people with diabetes(3), characterized by an initial hypersecretion of in-
sulin due to a reduced sensitivity to insulin in the cells, which over time may lead to 
a decreased secretion of insulin and resulting hyperglycemia(17). Obese individuals 
have ~30% lower insulin sensitivity than lean people, however, insulin resistance may 
also occur among lean people which suggests that the pathogenesis in some cases 
are independent of body fat(17). However, obesity is still the main predictor for type 
2 diabetes where individuals with obesity may suffer a 7-fold risk of incident type 2 
diabetes compared to individuals with normal weight(18). There are also less common 
subgroups of diabetes such as Latent Autoimmune Diabetes in Adults (LADA), with 
a prevalence ~10% of the population with diabetes and MODY with an estimated 
prevalence of ~1-5% of the population with diabetes, although the prevalence of all 
diabetes types may vary depending on population and classi cation methods(3).
The increasing numbers of overweight and obesity in the general popu-
lation
In the industrialized western society, body weight has increased dramatically the last 
decades, particularly in English-speaking nations, however, mean body mass index 
(BMI) has increased among Swedish citizens in both adolescents and adults and in 
both sexes(19). The increasing rates of obesity may lead to rising rates of cardiovascular 
disease (CVD), heart failure (HF)(20) and type 2 diabetes in the general population, 
which may be concerning from a public health perspective. 
Large registry- and cohort-based studies has shown that BMI is a predictor for mortal-
ity in the general population, with increasing hazard ratios (HRs) starting below BMI 
25 kg/m2(21-23), con rming that overweight and obesity is associated with death and 
CVD complications.
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Epidemiology of type 2 diabetes - prevalence and the excess risks of late 
complications
The increasing prevalence of type 2 diabetes worldwide is taking epidemic propor-
tions. Fourhundred sixtytwo million individuals i.e 6.28% of the world’s population 
is estimated to suffer from type 2 diabetes(24). Similar to the distribution of obesity, the 
industrialized western society and the Paci c Ocean nations have the highest preva-
lence of type 2 diabetes(24). With increasing rates of obesity, the prevalence of type 2 
diabetes in the Swedish adult population could, in a worst-case scenario, be estimated 
to be >12% by the year 2050(25). These numbers may be worrying due to the excess 
risks of mortality(26, 27) and several CVD outcomes including HF(27, 28). Glycemic con-
trol and kidney function are two crucial predictors of mortality, where poor glycemic 
control is thought to initiate a 4-fold excess risk of mortality in patients aged <55 
years, while an estimated glomerular  ltration rate (eGFR)<15 mL/min/1.73 m2 may 
lead to an excess risk of 14 times that of the general population(26). Likewise, younger 
individuals with type 2 diabetes have been shown to have a 4-fold risk of HF com-
pared to the general population(28). Not only may glycemic control and kidney func-
tion play an important role as independent predictors of late complications, but over-
all inadequate risk factor control, such as the accumulated burden of hyperglycemia, 
dyslipidemia, elevated blood pressure, smoking and albuminuria not at target, has 
also been shown to in uence the excess risks of mortality and CVD, with markedly 
elevated risks of these outcomes when target levels are not reached, however, among 
non-smokers and CVD risk factors at target, the absolute risk may be on a par with the 
risk of the general population, or just slightly higher(27). Treatment of CVD risk factors 
such as lipid-lowering and antihypertensive treatment along with intensive glycemic 
regimens may reduce risks among patients with type 2 diabetes signi cantly(29).   
Type 2 diabetes, BMI, mortality and CVD outcomes
The incidence of type 2 diabetes is strongly associated with overweight and obesity(30), 
thus increasing rates of type 2 diabetes might be a logical consequence of rising obe-
sity rates globally. However, the effect of BMI on mortality and CVD in individuals 
already diagnosed with type 2 diabetes has been debated. Some studies have sug-
gested an inverse association between body weight and mortality where increased 
body weight would be protective(31), and others where higher weight in patients with 
type 2 diabetes would be associated with higher mortality(32-34), while one study pro-
poses a near linear positive association between BMI and mortality(35). Such diverse 
results from the research community may lead to confusing messages to clinicians 
and patients alike. What may be more apparent is the increased risk of HF with in-
creasing BMI, where reports are sparse compared to the outcome of mortality, with 
no increased risk among leaner men and just slightly elevated risk of HF among the 
leanest women (BMI 18.5-22.5 kg/m2), and with an approximately 2-fold risk of HF 
in patients with BMI >40 kg/m2(36). How BMI relates to adverse outcomes in the co-
hort of patients diagnosed with type 2 diabetes compared to a general population has, 
however, been sparsely studied. The increased risk for HF among obese individuals 
with type 2 diabetes is thought to re ect obesity related complications(37) whereas in-
cident HF has not declined to the same degree as acute myocardial infarction (AMI) 
and stroke in recent years(38), possibly indicating different pathophysiological mecha-
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nisms. While the independent role of hemoglobin A1c (HbA1c) as predictor for ath-
erosclerotic complications such as CVD death(26) as well as for HF(28) may also raise 
the question if obesity may be a stronger predictor of HF than for AMI and also about 
how the combined effect of type 2 diabetes, hyperglycemia and obesity relates to the 
risk of incident HF.
Epidemiology of type 1 diabetes - incidence of type 1 diabetes and the 
excess risks of late complications
The Nordic countries have among the highest annual incidence of type 1 diabetes 
in the world, with rates in Sweden only second to Finland with approximately 40 
individuals diagnosed with type 1 diabetes per 100,000 inhabitants per year(12). Even 
though the Swedish prevalence of type 1 diabetes is much lower than that of type 2 
diabetes, type 1 diabetes usually starts early in life which may impair quality of life 
lifelong for many individuals worldwide(39). An American study concluded that, over 
a lifetime, the excess societal costs for type 1 diabetes would be >$800 billion(40), 
However, incidence rates of type 1 diabetes may have levelled off in Finland, with a 
decrease among children but rates were continuing to increase in Sweden at least until 
2015(41). 
The excess risk of mortality and CVD complications including HF in type 1 diabetes, 
compared to the general population has been studied extensively. Hyperglycemia is 
probably the most important predictor of mortality and CVD, where patients with 
HbA1c levels ≥83 mmol/mole displayed an 8-fold risk of death and a 10-fold risk of 
death from CVD in comparison to the general population, and 29-fold respectively 
41-fold risk of death and death from CVD causes in the case of stage 5 chronic kidney 
disease (CKD)(42). Similar to type 2 diabetes, inadequate overall risk factor control of 
HbA1c, low-density lipoprotein (LDL) cholesterol and systolic blood pressure (SBP) 
to target levels, presence of albuminuria and being a smoker are associated with in-
creasing excess risks of mortality and CVD, where risk increases with an increasing 
number of risk factors not reaching target levels(43). 
Type 1 diabetes, BMI, mortality and CVD outcomes
The role of obesity as a predictor for mortality and CVD outcomes in type 1 diabetes 
are sparse and the associations found between BMI and mortality heterogeneous. In-
creased risks have been observed among patients with type 1 diabetes with BMI <18.5 
kg/m2, BMI <20 kg/m2, while African Americans with type 1 diabetes displayed an 
obesity paradox (5% less probability to die per one unit increase in BMI)(44). Weight 
loss among patients with type 1 diabetes has been suggested to be associated with 
increased mortality risk(45). 
Concurrently, intensive insulin therapy has been shown to reduce blood glucose, with 
an initial reduced risk of CVD compared to the conventionally treated group, how-
ever, with the side effect of weight gain(46), the intensive therapy group after 13 years 
of follow-up went from lower risk of CVD to risk that was equivalent to that of the 
conventional therapy group(55). With new recommendations on how to tackle phe-
nomena such as reverse causality taking factors such as follow-up time, smoking and 
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frailty into consideration, previously  ndings of paradoxical effects of obesity with 
increased risks in normal weight individuals may be challenged and possibly lead to 
new discoveries or con rmations about why results might contradict the common 
recommendations of maintaining low weight and achieving weight loss among obese 
individuals in the general population. 
Reverse causality in epidemiological studies
Residual confounding is a phenomenon thought to prevent researchers to discover 
causal relationships by unprecise or unreliable measurements(47), i.e the exact num-
ber of smoked cigarettes among smokers(21). Residual confounding is acknowledged 
by many researchers, however, another phenomenon called reverse causality is less 
understood but may also lead to confusing results and unexpected associations to ad-
verse outcomes(47). Where obesity is found to be protective, sometime called an obesi-
ty paradox, this may be because there is confounding by other factors associated with 
lower weight, such as cigarette smoking, frailty, but also hidden diseases that may 
affect  ndings during a too short follow-up time and other coexisting conditions(47,48). 
Some examples of studies considering such factors are Tobias DK et al.(35) who found 
a stepwise increase in mortality by BMI among patients with type 2 diabetes and 
Adamsson Eryd et al.(49), who identi ed lower risk of CVD events in patients with 
type 2 diabetes with SBP as low as <130 mmHg after the consideration of coexisting 
conditions. Hence, it is evident that factors that may contribute to reverse causality 
should be carefully considered when analyzing and interpreting epidemiological data. 
Age at onset in type 1 diabetes
Recently published research from the Swedish national diabetes registry (NDR) dis-
plays a novel  nding about the importance from age at onset, where death and the 
risk of late CVD complications were multiple times higher among patients with onset 
of type 1 diabetes at a young age (0-15 years) and where the estimated life span was 
roughly a decade lower than for age- and sex matched controls(50). Reasons for the el-
evated risks of late complications may be explained by the glycemic load which may 
be greater among individuals with an onset of diabetes at the age of 15 years or less(50). 
These  ndings along with the proposed importance of risk factor control(43), may lead 
to the question if risk factor trajectories over a life-span could provide some answers 
to the proposed high excess risks of mortality and late complications demonstrated for 
patients with an early onset of type 1 diabetes.
16
nisms. While the independent role of hemoglobin A1c (HbA1c) as predictor for ath-
erosclerotic complications such as CVD death(26) as well as for HF(28) may also raise 
the question if obesity may be a stronger predictor of HF than for AMI and also about 
how the combined effect of type 2 diabetes, hyperglycemia and obesity relates to the 
risk of incident HF.
Epidemiology of type 1 diabetes - incidence of type 1 diabetes and the 
excess risks of late complications
The Nordic countries have among the highest annual incidence of type 1 diabetes 
in the world, with rates in Sweden only second to Finland with approximately 40 
individuals diagnosed with type 1 diabetes per 100,000 inhabitants per year(12). Even 
though the Swedish prevalence of type 1 diabetes is much lower than that of type 2 
diabetes, type 1 diabetes usually starts early in life which may impair quality of life 
lifelong for many individuals worldwide(39). An American study concluded that, over 
a lifetime, the excess societal costs for type 1 diabetes would be >$800 billion(40), 
However, incidence rates of type 1 diabetes may have levelled off in Finland, with a 
decrease among children but rates were continuing to increase in Sweden at least until 
2015(41). 
The excess risk of mortality and CVD complications including HF in type 1 diabetes, 
compared to the general population has been studied extensively. Hyperglycemia is 
probably the most important predictor of mortality and CVD, where patients with 
HbA1c levels ≥83 mmol/mole displayed an 8-fold risk of death and a 10-fold risk of 
death from CVD in comparison to the general population, and 29-fold respectively 
41-fold risk of death and death from CVD causes in the case of stage 5 chronic kidney 
disease (CKD)(42). Similar to type 2 diabetes, inadequate overall risk factor control of 
HbA1c, low-density lipoprotein (LDL) cholesterol and systolic blood pressure (SBP) 
to target levels, presence of albuminuria and being a smoker are associated with in-
creasing excess risks of mortality and CVD, where risk increases with an increasing 
number of risk factors not reaching target levels(43). 
Type 1 diabetes, BMI, mortality and CVD outcomes
The role of obesity as a predictor for mortality and CVD outcomes in type 1 diabetes 
are sparse and the associations found between BMI and mortality heterogeneous. In-
creased risks have been observed among patients with type 1 diabetes with BMI <18.5 
kg/m2, BMI <20 kg/m2, while African Americans with type 1 diabetes displayed an 
obesity paradox (5% less probability to die per one unit increase in BMI)(44). Weight 
loss among patients with type 1 diabetes has been suggested to be associated with 
increased mortality risk(45). 
Concurrently, intensive insulin therapy has been shown to reduce blood glucose, with 
an initial reduced risk of CVD compared to the conventionally treated group, how-
ever, with the side effect of weight gain(46), the intensive therapy group after 13 years 
of follow-up went from lower risk of CVD to risk that was equivalent to that of the 
conventional therapy group(55). With new recommendations on how to tackle phe-
nomena such as reverse causality taking factors such as follow-up time, smoking and 
17
frailty into consideration, previously  ndings of paradoxical effects of obesity with 
increased risks in normal weight individuals may be challenged and possibly lead to 
new discoveries or con rmations about why results might contradict the common 
recommendations of maintaining low weight and achieving weight loss among obese 
individuals in the general population. 
Reverse causality in epidemiological studies
Residual confounding is a phenomenon thought to prevent researchers to discover 
causal relationships by unprecise or unreliable measurements(47), i.e the exact num-
ber of smoked cigarettes among smokers(21). Residual confounding is acknowledged 
by many researchers, however, another phenomenon called reverse causality is less 
understood but may also lead to confusing results and unexpected associations to ad-
verse outcomes(47). Where obesity is found to be protective, sometime called an obesi-
ty paradox, this may be because there is confounding by other factors associated with 
lower weight, such as cigarette smoking, frailty, but also hidden diseases that may 
affect  ndings during a too short follow-up time and other coexisting conditions(47,48). 
Some examples of studies considering such factors are Tobias DK et al.(35) who found 
a stepwise increase in mortality by BMI among patients with type 2 diabetes and 
Adamsson Eryd et al.(49), who identi ed lower risk of CVD events in patients with 
type 2 diabetes with SBP as low as <130 mmHg after the consideration of coexisting 
conditions. Hence, it is evident that factors that may contribute to reverse causality 
should be carefully considered when analyzing and interpreting epidemiological data. 
Age at onset in type 1 diabetes
Recently published research from the Swedish national diabetes registry (NDR) dis-
plays a novel  nding about the importance from age at onset, where death and the 
risk of late CVD complications were multiple times higher among patients with onset 
of type 1 diabetes at a young age (0-15 years) and where the estimated life span was 
roughly a decade lower than for age- and sex matched controls(50). Reasons for the el-
evated risks of late complications may be explained by the glycemic load which may 
be greater among individuals with an onset of diabetes at the age of 15 years or less(50). 
These  ndings along with the proposed importance of risk factor control(43), may lead 
to the question if risk factor trajectories over a life-span could provide some answers 
to the proposed high excess risks of mortality and late complications demonstrated for 




Based on the heterogeneous results from previous research the aim of the study was 
to investigate the relationship between BMI, mortality and CVD mortality among 
patients with type 2 diabetes, taking factors into account known to in uence  ndings 
by reverse causality.
Study II
Based on the proposed obesity paradox that has been observed in patients with type 1 
diabetes, where previous research exhibited increased mortality among patients with 
type 1 diabetes and low weight and among patients who experienced weight loss, we 
wanted to investigate associations between BMI, mortality and other CVD outcomes 
including HF by taking factors potentially associated with reverse causality into con-
sideration. 
Study III
With the supposedly different pathophysiological mechanisms behind atherosclerotic 
disease and HF, we aimed to investigate the excess risk of HF and AMI by the com-
bined exposures of BMI and HbA1c among patients with type 2 diabetes.
Study IV
Since onset of type 1 diabetes at an early age has been associated with a shortened 
life span and higher risk of complications, we aimed to study trajectories of glycemic 




The study population comprised patients with type 1 diabetes and type 2 diabetes 
registered in NDR between 1998 and 2012. In Study I and Study III we aimed to de-
scribe the excess risk for our main exposures by using controls taken from the general 
population (“Total population register” [RTB]), matched by age, sex and county. In 
order to identify coexisting conditions and de ne the outcomes we used the Swedish 
in-patient registry, which has been validated to a positive predicted value of ~85-95% 
of major CVD outcomes(51) and the cause of death registry, while identi cation of so-
cioeconomic factors was taken from the Longitudinal Database for Health Insurance 
and Labor Market (LISA)-registry. All registries were linked via the personal identi -
cation number (PIN), unique for every Swedish citizen, thus allowing for studying the 























Figure 1. Linked registries via PIN.
The NDR has currently an approximate coverage of 95% of Swedish type 2 diabetes 
patients and roughly 90% of the type 1 diabetes population, where our studies include 
more than 100,000 patients with type 2 diabetes and more than 30,000 patients with 
type 1 diabetes. The ethics review board at the University of Gothenburg approved the 
study, with informed written or oral consent obtained from each patient in NDR. For 
Study I-IV all patients were intially registered between 1998-2012. 
Study I initially comprised 457,473 patients with type 2 diabetes and 2,287,365 
matched controls. We excluded 26,215 controls because of inconsistent follow-up 
data, probably caused by reused PIN. Other exclusions: 1) Patients with BMI <20 
were excluded along with their matched controls (patients and controls after exclu-
sion, n=452,999 and n=2,239,239, respectively), 2) Patients with >5 years of diabetes 
duration were excluded along with their matched controls, in order to avoid survival 




Based on the heterogeneous results from previous research the aim of the study was 
to investigate the relationship between BMI, mortality and CVD mortality among 
patients with type 2 diabetes, taking factors into account known to in uence  ndings 
by reverse causality.
Study II
Based on the proposed obesity paradox that has been observed in patients with type 1 
diabetes, where previous research exhibited increased mortality among patients with 
type 1 diabetes and low weight and among patients who experienced weight loss, we 
wanted to investigate associations between BMI, mortality and other CVD outcomes 
including HF by taking factors potentially associated with reverse causality into con-
sideration. 
Study III
With the supposedly different pathophysiological mechanisms behind atherosclerotic 
disease and HF, we aimed to investigate the excess risk of HF and AMI by the com-
bined exposures of BMI and HbA1c among patients with type 2 diabetes.
Study IV
Since onset of type 1 diabetes at an early age has been associated with a shortened 
life span and higher risk of complications, we aimed to study trajectories of glycemic 




The study population comprised patients with type 1 diabetes and type 2 diabetes 
registered in NDR between 1998 and 2012. In Study I and Study III we aimed to de-
scribe the excess risk for our main exposures by using controls taken from the general 
population (“Total population register” [RTB]), matched by age, sex and county. In 
order to identify coexisting conditions and de ne the outcomes we used the Swedish 
in-patient registry, which has been validated to a positive predicted value of ~85-95% 
of major CVD outcomes(51) and the cause of death registry, while identi cation of so-
cioeconomic factors was taken from the Longitudinal Database for Health Insurance 
and Labor Market (LISA)-registry. All registries were linked via the personal identi -
cation number (PIN), unique for every Swedish citizen, thus allowing for studying the 























Figure 1. Linked registries via PIN.
The NDR has currently an approximate coverage of 95% of Swedish type 2 diabetes 
patients and roughly 90% of the type 1 diabetes population, where our studies include 
more than 100,000 patients with type 2 diabetes and more than 30,000 patients with 
type 1 diabetes. The ethics review board at the University of Gothenburg approved the 
study, with informed written or oral consent obtained from each patient in NDR. For 
Study I-IV all patients were intially registered between 1998-2012. 
Study I initially comprised 457,473 patients with type 2 diabetes and 2,287,365 
matched controls. We excluded 26,215 controls because of inconsistent follow-up 
data, probably caused by reused PIN. Other exclusions: 1) Patients with BMI <20 
were excluded along with their matched controls (patients and controls after exclu-
sion, n=452,999 and n=2,239,239, respectively), 2) Patients with >5 years of diabetes 
duration were excluded along with their matched controls, in order to avoid survival 
bias and to obtain a cohort relevant to modern treatment (patients and controls left 
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after exclusion, n=256,078 and n=1,268,540, respectively), 3) Patients and controls 
were excluded along with their matched set, if there was a history of cancer or demen-
tia at baseline (patients and controls left after exclusion, n=172,090 and n=857,129, 
respectively), 4) For the sake of performing analyses based on short- and long term 
follow-up, patients with zero days of follow-up were excluded (patients and con-
trols left after exclusion, n=172,087 and n=857,110, respectively), 5) Patient who had 
missing BMI were excluded along with their matched controls. After exclusions, the 
 nal cohort comprised 149,345 patients with type 2 diabetes and 743,907 controls.
Study II consisted of two separate cohorts, one for the start time at baseline and an-
other cohort for the analyses of updated BMI with the new start time set to most re-
cent measured BMI, measured 1-5 years from baseline. The initial cohort comprised 
36,872 patients with type 1 diabetes, patients were then excluded if 1) not de ned 
as type 1 diabetes (4,329 patients excluded), 2) due to previous cardiovascular con-
ditions (AMI, stroke, CHD, AF or HF, renal dialysis/transplantation or amputation; 
1,846 patients), 3) with BMI <18.5 kg/m2 (483 patients excluded), 4) with missing 
BMI (4,089 patients excluded). After exclusions, the  nal baseline cohort comprised 
26,125 patients for the  nal analyses. The follow-up cohort was based on the baseline 
cohort, where we additionally excluded patients if: 1) <2 visits or follow-up time <1 
year (during the  rst  ve years of follow-up since baseline) (3,822 patients excluded), 
2) patients who died within  ve years, or patients with a follow-up time of <5 years 
from baseline or events occurring, i.e AMI, stroke, AF, CHD or HF during this period 
(3,324 patients excluded). Thus, the  nal updated cohort for follow-up consisted of 
18,979 patients.
The original cohort in Study III consisted of 457,473 patients and 2,287,365 controls. 
We excluded 1) Patients and controls if they had inconsistent survival data 2) Patients 
and controls with survival time zero 3) The complete matched set (1 patient along 
with 5 comparators) if a patient or control had a previous diagnosis of AMI, stroke, 
CHD or HF (patients and controls left after exclusions, n=216,183 and n=1,077,471, 
respectively), 4) if the patient had BMI <18.5 (patients and controls left after exclu-
sions, n=215,590 and n=1,074,521, respectively) 5) Patients with missing BMI after 
imputation (patients and controls left after exclusions n=181,045, n=902,302 respec-
tively) 
The cohort in Study IV initially comprised 36,872 patients with type 1 diabetes. Af-
ter exclusion of patients with: 1) Inconsistent follow-up data (3 patients excluded), 
2) Other clinical de nitions of diabetes than type 1 diabetes (4,286 patients excluded), 
3) Age ≥76 years (163 patients excluded), 4) Previous registered amputation or CKD, 
de nd as renal dialysis/transplantation or eGFR <15 mL/min/1.73 m2 (415 patients 
excluded), the  nal cohort comprised 32,005 individuals with type 1 diabetes.
Defi nitions of type 1 diabetes and type 2 diabetes
For type 2 diabetes we used the epidemiological de nition which comprised patients 
treated with diet only; oral antihyperglycemic treatment or ≥40 years of age in the 
case of insulin treatment with or without oral antihyperglycemic agents (Study I and 
III). For type 1 diabetes we used the epidemiological de nition where patients had an 
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age at onset ≤30 years of age, treated with insulin only and further combined with a 
clinical de nition where the caregiving physician had set the current diagnosis as type 
1 diabetes (Study II and IV). 
Variables from NDR
See Figure 2.
Figure 2. Description of variables from NDR.
Outcomes
For Study I-III we used ICD-9 and ICD-10 where outcomes and preexisting condi-
tions were de ned as: CVD mortality (I00-I99 as underlying cause of death [Study I]); 
CVD mortality (I20-I25, I61, I63, I64, I67.9 [Study II]); major CVD (I21, I61, I62.9, 
I63, I64, I67.9 [Study III]);  AMI (410, I21); stroke (431, 432X, 433, 434, 436, 437X, 
I61, I62.9, I63, I64, I67.9); HF (428, I50); atrial  brillation (AMI), [427D, I48]); renal 
dialysis or transplantation (V42A, V45B, V56A, V56W, Z94.0, Z49, Z99.2); cancer 
(140-208, C00-C97); dementia (G30, F00-D03, F05); amputation (NHQ09, NHQ11, 
NHQ12, NHQ13, NHQ14, NHQ16, NHQ17, NHQ99, NGQ09, NGQ19, NGQ99, 
NFQ19, NFQ99).
Statistical analyses
All statistical analyses were performed with R (R Foundation for Statistical Program-
ming).
Study I
Analyses of the outcomes
Crude incidence rates by BMI were calculated with con dence intervals (CI) 95% 
per 1,000 person years. Cox regression was used to analyze the risk of mortality and 
CVD mortality. Patients were strati ed into  ve BMI categories: 20-<25, 25-<30, 
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Outcomes
For Study I-III we used ICD-9 and ICD-10 where outcomes and preexisting condi-
tions were de ned as: CVD mortality (I00-I99 as underlying cause of death [Study I]); 
CVD mortality (I20-I25, I61, I63, I64, I67.9 [Study II]); major CVD (I21, I61, I62.9, 
I63, I64, I67.9 [Study III]);  AMI (410, I21); stroke (431, 432X, 433, 434, 436, 437X, 
I61, I62.9, I63, I64, I67.9); HF (428, I50); atrial  brillation (AMI), [427D, I48]); renal 
dialysis or transplantation (V42A, V45B, V56A, V56W, Z94.0, Z49, Z99.2); cancer 
(140-208, C00-C97); dementia (G30, F00-D03, F05); amputation (NHQ09, NHQ11, 
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NFQ19, NFQ99).
Statistical analyses
All statistical analyses were performed with R (R Foundation for Statistical Program-
ming).
Study I
Analyses of the outcomes
Crude incidence rates by BMI were calculated with con dence intervals (CI) 95% 
per 1,000 person years. Cox regression was used to analyze the risk of mortality and 
CVD mortality. Patients were strati ed into  ve BMI categories: 20-<25, 25-<30, 
22
30-<35, 35-<40, and ≥40 kg/m2. We studied all-cause mortality and CVD mortality, 
short-term (outcomes that occurred within ≤5 years from baseline) as well as long-
term (outcomes that occurred ≥5 years from baseline) overall and strati ed by age: 
<65 and ≥65 years of age. In the short-term perspective data from patients and  ve 
age- and sex matched control subjects from the general population was used, while 
for the long-term perspective, data from patients and controls who survived the initial 
time-period was used. In the case of censoring or death, no reassigning of controls 
were done, thus censoring each patient and control subject individually. Each analysis 
was done separately per BMI group in order to  t the Cox regression model.  
We adjusted the analysis for age by stratifying age into the overall HR, i.e quintiles 
of (18-50], (50-57], (57-63], (63-69] and (69- 101) years and by stratifying years of 
inclusion into the overall HR, i.e  ve equal-sized quintiles of (1998-2004], (2004-
2007], (2007-2009], (2009-2010] and (2010-2012). 
Additionally, the models were adjusted for sex, income, education, immigrant status, 
marital status, CHD, AMI, AF, renal dialysis/transplantation, HF and for the interac-
tion between diabetes duration by age. If variables did not ful ll the assumption of 
proportional hazard varibles, likewise to age and years of inclusion, were strati ed 
into the overall HR. 
In order to stratify the continuous variable of income, income was divided into equally 
sized quartiles. Analyses which did not ful ll the long-term assumption of propor-
tional hazards were tested with censoring at 12 years, if no substantial difference was 
observed we considered the model acceptable. 
All tests were two-tailed and a value of 0.05 was considered statistically signi cant. 
The assumption of proportional hazards was ful lled after strati cations.
Study II
BMI trajectories by year
Mixed linear regression was used to calculate the trajectories in BMI by calendar year 
from 1998-2012. We used 275,111 visits with registered BMI among 32,543 patients. 
Calendar year was set as  xed effect and adjusted for age, sex and diabetes duration 
with random effects set as random participant effect and as trend among subjects. To 
calculate mean BMI per calendar year, least square means were used with 95% CI.
Analyses of the outcomes
Crude incidence rates were calculated with CI 95% per 1,000 person years by BMI. 
Analyses regarding the outcomes of mortality, CVD mortality, major CVD event and 
HF were calculated using Cox regression adjusted for age, sex, duration of diabetes, 
marital status, immigrant status, income, education, smoking status and HbA1c, where 
BMI 25 kg/m2 was set as reference. BMI was modelled using restricted cubic splines 
with three equally tied knots. We further analyzed the outcome of mortality reduc-
ing factors known to cause reverse causation, i.e we stepwise excluded 1) smokers, 
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2) smokers and patients with HbA1c ≥60 mmol/mole and lastly 3) smokers, patients 
with HbA1c ≥60 mmol/mole and patients with 2002 as the latest year of registration. 
In a second cohort (see de nition of the follow-up cohort in study population [Study
II]) we used Cox regression to analyze how a change in BMI could in uence the 
selected outcomes. BMI change was calculated by the absolute change in BMI be-
tween 1-5 years (last measured BMI minus baseline BMI), divided by days between 
measurements, then multiplied with 365.25 to receive the estimated yearly change in 
BMI. The new baseline was set to last registered BMI within the  rst  ve years from 
the day of inclusion in NDR. To analyze mortality, CVD mortality, major CVD event 
and HF, groups of <0; 0-<0.25 (reference); 0.25-<0.75; ≥0.75 kg/m2 per year was used 
in Cox regression with cubic splines tied to three equally sized knots. 
We assessed the Cox proportional hazard using Schoenfeld’s residuals. The propor-
tional hazard assumption was considered to be ful lled. 
Study III
Analyses of the outcomes
Age adjusted incidence rates for HF and AMI were calculated with 95% CI per 1,000 
person years. Outcomes were analyzed by Cox regression models using  ve BMI 
groups of; 18.5-<25, 25-<30, 30-<35, 35-<40, and ≥40 kg/m2. For each BMI cat-
egory three HbA1c groups were used; <53, 53-70 and ≥71 mmol/mole. Age- and sex 
matched control subjects were used as reference for each HbA1c group, which were 
examined separately, thus generating three models by HbA1c with the main exposure 
of  ve BMI groups. The Cox regression models were adjusted for age, sex, diabetes 
duration, education, income, immigrant status, marital status, atrial  brillation and 
renal dialysis/transplantation. The adjustment for diabetes was centered around the 
grand mean, thus representing the excess risk of AMI and HF with a 4.3 years duration 
of diabetes. We checked the analyses by using HF as the principal diagnosis only with 
similar results as the main  ndings. 
AMI and HF were further analyzed with Cox regression, without using control sub-
jects with the purpose of determining the association between the outcomes and BMI 
and HbA1c respectively. Models were adjusted for age, sex, socioeconomic factors, 
LDL-cholesterol, SBP and smoking status. BMI and continuous risk factors were 
modelled using cubic splines tied into equally tied knots. Since 8,622 patients with 
type 2 diabetes were diagnosed with AMI prior or the same day to the diagnosis of HF, 
we checked the association between BMI and HF by a time-updated Cox regression 
including adjustment for BMI, AMI during follow-up and the interaction term BMI 
by AMI during follow-up. Where AMI and HF occurred at the same day, one day was 
added to the follow-up time of HF. 
The proportional hazards assumption was checked with Schoenfeldt´s residuals and 
there were no signi cant deviations from the assumption. The analyses were two-
tailed where a value of 0.05 was considered statistically signi cant. 
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were done, thus censoring each patient and control subject individually. Each analysis 
was done separately per BMI group in order to  t the Cox regression model.  
We adjusted the analysis for age by stratifying age into the overall HR, i.e quintiles 
of (18-50], (50-57], (57-63], (63-69] and (69- 101) years and by stratifying years of 
inclusion into the overall HR, i.e  ve equal-sized quintiles of (1998-2004], (2004-
2007], (2007-2009], (2009-2010] and (2010-2012). 
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marital status, CHD, AMI, AF, renal dialysis/transplantation, HF and for the interac-
tion between diabetes duration by age. If variables did not ful ll the assumption of 
proportional hazard varibles, likewise to age and years of inclusion, were strati ed 
into the overall HR. 
In order to stratify the continuous variable of income, income was divided into equally 
sized quartiles. Analyses which did not ful ll the long-term assumption of propor-
tional hazards were tested with censoring at 12 years, if no substantial difference was 
observed we considered the model acceptable. 
All tests were two-tailed and a value of 0.05 was considered statistically signi cant. 
The assumption of proportional hazards was ful lled after strati cations.
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BMI trajectories by year
Mixed linear regression was used to calculate the trajectories in BMI by calendar year 
from 1998-2012. We used 275,111 visits with registered BMI among 32,543 patients. 
Calendar year was set as  xed effect and adjusted for age, sex and diabetes duration 
with random effects set as random participant effect and as trend among subjects. To 
calculate mean BMI per calendar year, least square means were used with 95% CI.
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Crude incidence rates were calculated with CI 95% per 1,000 person years by BMI. 
Analyses regarding the outcomes of mortality, CVD mortality, major CVD event and 
HF were calculated using Cox regression adjusted for age, sex, duration of diabetes, 
marital status, immigrant status, income, education, smoking status and HbA1c, where 
BMI 25 kg/m2 was set as reference. BMI was modelled using restricted cubic splines 
with three equally tied knots. We further analyzed the outcome of mortality reduc-
ing factors known to cause reverse causation, i.e we stepwise excluded 1) smokers, 
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In a second cohort (see de nition of the follow-up cohort in study population [Study
II]) we used Cox regression to analyze how a change in BMI could in uence the 
selected outcomes. BMI change was calculated by the absolute change in BMI be-
tween 1-5 years (last measured BMI minus baseline BMI), divided by days between 
measurements, then multiplied with 365.25 to receive the estimated yearly change in 
BMI. The new baseline was set to last registered BMI within the  rst  ve years from 
the day of inclusion in NDR. To analyze mortality, CVD mortality, major CVD event 
and HF, groups of <0; 0-<0.25 (reference); 0.25-<0.75; ≥0.75 kg/m2 per year was used 
in Cox regression with cubic splines tied to three equally sized knots. 
We assessed the Cox proportional hazard using Schoenfeld’s residuals. The propor-
tional hazard assumption was considered to be ful lled. 
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Analyses of the outcomes
Age adjusted incidence rates for HF and AMI were calculated with 95% CI per 1,000 
person years. Outcomes were analyzed by Cox regression models using  ve BMI 
groups of; 18.5-<25, 25-<30, 30-<35, 35-<40, and ≥40 kg/m2. For each BMI cat-
egory three HbA1c groups were used; <53, 53-70 and ≥71 mmol/mole. Age- and sex 
matched control subjects were used as reference for each HbA1c group, which were 
examined separately, thus generating three models by HbA1c with the main exposure 
of  ve BMI groups. The Cox regression models were adjusted for age, sex, diabetes 
duration, education, income, immigrant status, marital status, atrial  brillation and 
renal dialysis/transplantation. The adjustment for diabetes was centered around the 
grand mean, thus representing the excess risk of AMI and HF with a 4.3 years duration 
of diabetes. We checked the analyses by using HF as the principal diagnosis only with 
similar results as the main  ndings. 
AMI and HF were further analyzed with Cox regression, without using control sub-
jects with the purpose of determining the association between the outcomes and BMI 
and HbA1c respectively. Models were adjusted for age, sex, socioeconomic factors, 
LDL-cholesterol, SBP and smoking status. BMI and continuous risk factors were 
modelled using cubic splines tied into equally tied knots. Since 8,622 patients with 
type 2 diabetes were diagnosed with AMI prior or the same day to the diagnosis of HF, 
we checked the association between BMI and HF by a time-updated Cox regression 
including adjustment for BMI, AMI during follow-up and the interaction term BMI 
by AMI during follow-up. Where AMI and HF occurred at the same day, one day was 
added to the follow-up time of HF. 
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tailed where a value of 0.05 was considered statistically signi cant. 
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Study IV
Analyses of risk factors
In Study IV risk factor trajectories were analyzed by mixed linear regression and gen-
eralized linear models. Age at onset was strati ed into groups consisting of: ≤10, 11-
15, 16-20, 21-25 and 26-30 years at onset where the main exposure was age (18-75 
years). Continuous outcomes (HbA1c, eGFR, LDL cholesterol, BMI, SBP and dia-
stolic blood pressure [DBP]) were analyzed by mixed linear regression adjusted for 
sex with  xed effects of age, age at onset, the interaction term age by age at onset and 
a random participant effect. Analyses with the outcomes of BMI, LDL cholesterol, 
SBP and DBP were additionally adjusted for smoking status, statins and antihyperten-
sives respectively. The outcomes of albuminuria (micro- or macro albuminuria) was 
modelled as a dichotomous variable analyzed by generalized linear models adjusted 
for sex with  xed effects of age groups de ned as 18–25 years, and then by 4-year 
intervals up to 75 years of age, age at onset, the interaction term age group by age 
at onset and a random participant effect. All analyses were analyzed by least square 
means in order to generate mean values for each speci c age, while albuminuria was 
back transformed into probability from the logit scale. Sex speci c analyses were 
performed separately on HbA1c, eGFR (albuminuria present), LDL cholesterol, BMI 
and SBP.
Baseline imputation
Machine learning algorithms were used to examine the relationship between baseline 
HbA1c (≥1 year duration of diabetes) and various risk factors for CVD, socioeconom-
ic status and previous CVD and HF. In order to obtain complete data, baseline vari-
ables were imputed with Multiple Imputation by Chained Equations (MICE), where 
missing data are imputed via mean values followed by linear and logistic regression. 
Imputed baseline data was solely used for machine learning models.
Machine learning
With a complete data set analyses were performed strati ed on age at onset: 0-15 and 
16-30 years of age and by sex. Two different algorithms were used, conditional ran-
dom forest and gradient boosting machines. The output displayed the models feature 
importance (ranking of predictors) and were also compared to ordinal Linear regres-
sion models. In most cases both of the machine learning algorithms were superior to 
linear regression, which may re ect the potential of these algorithms with respect to 




The study population comprised 149,345 patients with type 2 diabetes and 743,907 
control subjects, where the median follow-up time was 5.5 years (mean age 59.5 
years). Incidence rates are shown by the  ve strati ed BMI categories: 20 to <25, 25 
to <30, 30 to <35, 35 to <40 and ³40 kg/m2. U-shaped curves were found short-term, 
with fairly low excess risk estimates compared to the general population (Figures 3 
and 4). However, long-term analyses exhibited an increase in excess risks with J-
shaped associations among patients with type 2 diabetes in the overall cohort as well 
as in the age strati ed analyses (17,546 deaths and 7,218 cases of CVD mortality). 
HR ranged from HR 1.09 (CI 95% 1.14-1.36) among patients with BMI 25-<30 kg/m2 
(nadir of the analysis; or the lowest risk) up to HR 2.00 (CI 95% 1.58-2.54) among pa-
tients with BMI ≥40 kg/m2, while patients with BMI 20-<25 displayed slightly higher 
risk of mortality than those of the nadir, with HR 1.55 (CI 95% 1.23-1.95) (Figure 3). 
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Figure 3. Adjusted HR for all-cause mortality according to BMI among patients with type 2 diabetes 
using age- and sex matched controls as reference*. 
Panel A, CVD mortality (overall), panel B, CVD mortality (<65 years), panel C, CVD mortality (≥65 
years). *American Diabetes Association [BMI and Mortality in Patients With New-Onset Type 2 Diabe-
tes: A Comparison With Age- and Sex-Matched Control Subjects From the General Population, Ameri-
can Diabetes Association, [2018]. Copyright and all rights reserved. Material from this publication has 
been used with the permission of American Diabetes Association. 
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for sex with  xed effects of age groups de ned as 18–25 years, and then by 4-year 
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at onset and a random participant effect. All analyses were analyzed by least square 
means in order to generate mean values for each speci c age, while albuminuria was 
back transformed into probability from the logit scale. Sex speci c analyses were 
performed separately on HbA1c, eGFR (albuminuria present), LDL cholesterol, BMI 
and SBP.
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ic status and previous CVD and HF. In order to obtain complete data, baseline vari-
ables were imputed with Multiple Imputation by Chained Equations (MICE), where 
missing data are imputed via mean values followed by linear and logistic regression. 
Imputed baseline data was solely used for machine learning models.
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16-30 years of age and by sex. Two different algorithms were used, conditional ran-
dom forest and gradient boosting machines. The output displayed the models feature 
importance (ranking of predictors) and were also compared to ordinal Linear regres-
sion models. In most cases both of the machine learning algorithms were superior to 
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control subjects, where the median follow-up time was 5.5 years (mean age 59.5 
years). Incidence rates are shown by the  ve strati ed BMI categories: 20 to <25, 25 
to <30, 30 to <35, 35 to <40 and ³40 kg/m2. U-shaped curves were found short-term, 
with fairly low excess risk estimates compared to the general population (Figures 3 
and 4). However, long-term analyses exhibited an increase in excess risks with J-
shaped associations among patients with type 2 diabetes in the overall cohort as well 
as in the age strati ed analyses (17,546 deaths and 7,218 cases of CVD mortality). 
HR ranged from HR 1.09 (CI 95% 1.14-1.36) among patients with BMI 25-<30 kg/m2 
(nadir of the analysis; or the lowest risk) up to HR 2.00 (CI 95% 1.58-2.54) among pa-
tients with BMI ≥40 kg/m2, while patients with BMI 20-<25 displayed slightly higher 
risk of mortality than those of the nadir, with HR 1.55 (CI 95% 1.23-1.95) (Figure 3). 
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Figure 3. Adjusted HR for all-cause mortality according to BMI among patients with type 2 diabetes 
using age- and sex matched controls as reference*. 
Panel A, CVD mortality (overall), panel B, CVD mortality (<65 years), panel C, CVD mortality (≥65 
years). *American Diabetes Association [BMI and Mortality in Patients With New-Onset Type 2 Diabe-
tes: A Comparison With Age- and Sex-Matched Control Subjects From the General Population, Ameri-
can Diabetes Association, [2018]. Copyright and all rights reserved. Material from this publication has 
been used with the permission of American Diabetes Association. 
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Figure 4. Adjusted HR for CVD mortality according to BMI among patients 
with type 2 diabetes using age- and sex matched controls as reference*
Panel A, CVD mortality (overall); panel B, CVD mortality (<65 years); pan-
el C, CVD mortality (≥65 years). *American Diabetes Association [BMI and 
Mortality in Patients With New-Onset Type 2 Diabetes: A Comparison With 
Age- and Sex-Matched Control Subjects From the General Population, 
American Diabetes Association, [2018]. Copyright and all rights reserved. 
Material from this publication has been used with the permission of Ameri-
can Diabetes Association. 
Corresponding  gures for the outcome of CVD mortality showed long-term HR of 
0.99 (CI 95% 0.90-1.09) among patients with BMI 25-<30 (nadir) and 2.00 (CI 95% 
1.37-2.91) in the most obese patients, while the group with normal weight (BMI 20-
<25) had an HR of 1.09 (CI 95% 0.95-1.26). We noted that the leanest participants 
did not differ signi cantly from matched controls (Figure 4). Age-strati ed analyses 
displayed similar associations, however with slight lower HR among patients <65 
years of age and slightly lower HR among the elderly compared to the overall cohort 
(Figures 3 and 4).
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Figure 5 shows an increasing trend in mean BMI ranging from 24.7 kg/m2 in 1998 to 
BMI 25.7 kg/m2 in 2012 among patients with type 1 diabetes. A fully adjusted Cox 
regression (Figure 6) showed a small but signi cant positive association with BMI 
for the outcomes of mortality, major CVD and HF, while the curve by BMI for CVD 
mortality was likewise positive but with no signi cant difference compared with the 
reference of 25 kg/m2. BMI <25 kg/m2 displayed no increased risk for neither CVD 
mortality, major CVD or HF. After excluding patients who were smokers at baseline, 
those with HbA1c >60 mmol/mole and those with a follow-up time <10 years, we did 
not identify any increased risk among patients with BMI less than the reference of 25 
kg/m2 for the outcome of mortality either. Among the 18,979 patients that were ana-
lyzed by updated BMI change (1-5 year from baseline) (Figure 6), we identi ed in-
creased risks for the outcome of mortality and HF among patients with a BMI change 
of ≥0.75 kg/m2/year. We noted no statistically signi cant increased risk for any of the 
outcomes among patients who experienced weight change <0 kg/m2/year compared to 

























Figure 5. Trends in BMI between the years 1998-2012 among patients with type 1 
diabetes overall and strati ed by sex*
*American Diabetes Association [BMI, Mortality, and Cardiovascular Outcomes in 
Type 1 Diabetes: Findings Against an Obesity Paradox, [2019]. Copyright and all 
rights reserved. Material from this publication has been used with the permission of 
American Diabetes Association. 
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Figure 6. Adjusted HR for mortality, CVD mortality, major CVD and HF according to BMI at base-
line and the estimated yearly BMI change among patients with type 1 diabetes* 
Panels A (HR by baseline BMI) & E (HR by estimated yearly change in BMI), All-cause mortality; 
panels B (HR by baseline BMI) & F (HR by estimated yearly change in BMI), CVD mortality; pan-
els C & G (HR by estimated yearly change in BMI), major CVD; panels D (HR by baseline BMI) & 
H (HR by estimated yearly change in BMI), HF. *American Diabetes Association [BMI, Mortality, 
and Cardiovascular Outcomes in Type 1 Diabetes: Findings Against an Obesity Paradox, [2019]. 
Copyright and all rights reserved. Material from this publication has been used with the permission 
of American Diabetes Association. 
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Study III
Among 185,045 patients with type 2 diabetes and 902,302 age- and sex matched 
control subjects, there were 33,060 cases of AMI and 28,855 cases of HF (out of 
which 12,821 patients had HF as the principal discharge diagnosis) within a median 
follow-up time of 5.7 years. The most essential  ndings were,  rstly, the  at rela-
tionship (incidence rates and HRs in Figures 7 and 8) observed between BMI and 
AMI where increased risks were mediated by poor glycemic control rather than BMI, 
whereas, secondly, we observed a strong, near linear increase in both incidence rates 
and adjusted HRs for HF by increasing BMI which worsened along with poor glyce-
mic control. For patients with type 2 diabetes and BMI ≥40 kg/m2 and HbA1c ≥71 
mmol/mole, the risk of heart failure was near 8-fold compared to that of age- and sex 
matched control subjects (Figure 8). There were similar trajectories regarding the risk 
of HF among the very obese patients in the analyses containing patients only and with 
additional adjustments for smoking status compared with reference level of 25 kg/m2 
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and their age- and sex matched
general population comparators
Figure 7. Age adjusted incidence rates per 1,000 person years for the outcomes of AMI and 
HF according to BMI and HbA1c among patients with type 2 diabetes and their age- and sex 
matched controls*
Panel A, AMI; panel B, HF. *Edqvist J, Rawshani A, Adiels M, Björck L, Lind M, Svensson 
AM, et al. Contrasting Associations of Body Mass Index and Hemoglobin A1c on the Excess 
Risk of Acute Myocardial Infarction and Heart Failure in Type 2 Diabetes Mellitus. J Am Heart 
Assoc. 2019;8(24). Open access. 
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Figure 6. Adjusted HR for mortality, CVD mortality, major CVD and HF according to BMI at base-
line and the estimated yearly BMI change among patients with type 1 diabetes* 
Panels A (HR by baseline BMI) & E (HR by estimated yearly change in BMI), All-cause mortality; 
panels B (HR by baseline BMI) & F (HR by estimated yearly change in BMI), CVD mortality; pan-
els C & G (HR by estimated yearly change in BMI), major CVD; panels D (HR by baseline BMI) & 
H (HR by estimated yearly change in BMI), HF. *American Diabetes Association [BMI, Mortality, 
and Cardiovascular Outcomes in Type 1 Diabetes: Findings Against an Obesity Paradox, [2019]. 
Copyright and all rights reserved. Material from this publication has been used with the permission 
of American Diabetes Association. 
29
Study III
Among 185,045 patients with type 2 diabetes and 902,302 age- and sex matched 
control subjects, there were 33,060 cases of AMI and 28,855 cases of HF (out of 
which 12,821 patients had HF as the principal discharge diagnosis) within a median 
follow-up time of 5.7 years. The most essential  ndings were,  rstly, the  at rela-
tionship (incidence rates and HRs in Figures 7 and 8) observed between BMI and 
AMI where increased risks were mediated by poor glycemic control rather than BMI, 
whereas, secondly, we observed a strong, near linear increase in both incidence rates 
and adjusted HRs for HF by increasing BMI which worsened along with poor glyce-
mic control. For patients with type 2 diabetes and BMI ≥40 kg/m2 and HbA1c ≥71 
mmol/mole, the risk of heart failure was near 8-fold compared to that of age- and sex 
matched control subjects (Figure 8). There were similar trajectories regarding the risk 
of HF among the very obese patients in the analyses containing patients only and with 
additional adjustments for smoking status compared with reference level of 25 kg/m2 




























Groups by HbA1c (mmol/mole)































Groups by HbA1c (mmol/mole)
and their age- and sex matched
general population comparators
Figure 7. Age adjusted incidence rates per 1,000 person years for the outcomes of AMI and 
HF according to BMI and HbA1c among patients with type 2 diabetes and their age- and sex 
matched controls*
Panel A, AMI; panel B, HF. *Edqvist J, Rawshani A, Adiels M, Björck L, Lind M, Svensson 
AM, et al. Contrasting Associations of Body Mass Index and Hemoglobin A1c on the Excess 
Risk of Acute Myocardial Infarction and Heart Failure in Type 2 Diabetes Mellitus. J Am Heart 
Assoc. 2019;8(24). Open access. 
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Figure 8. Adjusted HR for AMI and HF according to BMI and HbA1c among patients with type 2 
diabetes compared to age- and sex matched controls*
Panel A, AMI; panel B, HF. *Edqvist J, Rawshani A, Adiels M, Björck L, Lind M, Svensson AM, 
et al. Contrasting Associations of Body Mass Index and Hemoglobin A1c on the Excess Risk of 
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Figure 9. Adjusted HR for AMI and HF according to BMI and HbA1c respectively among patients 
with type 2 diabetes only, reference level was set to 25 kg/m2
Panel A, AMI; panel B, HF. *Edqvist J, Rawshani A, Adiels M, Björck L, Lind M, Svensson AM, 
et al. Contrasting Associations of Body Mass Index and Hemoglobin A1c on the Excess Risk of 
Acute Myocardial Infarction and Heart Failure in Type 2 Diabetes Mellitus. J Am Heart Assoc. 
2019;8(24). Open access. 
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Study IV
Analyses among 30,005 patients with type 1 diabetes showed trajectories of increased 
HbA1c levels (~70 mmol/mole) applicable to patients with an age at onset ≤15 years, 
and aged 18-30 years, HbA1c then declined to ~65 mmol/mole by age in the early 30s. 
For patients with an onset of type 1 diabetes ≥16 years or older, HbA1c in contrast 
increased annually from the age of onset beginning approximately at 55 mmol/mole 
which levelled off at and converged towards a level similar to the patients with an 
earlier age at onset at ~65 mmol/mole. Thus, patients regardless of the age of onset 
displayed similar mean HbA1c from approximately the age of 40 with some uncer-
tainty during the last ten years of the observed age span. Patients with an age at onset 
≤15 years displayed earlier probability of albuminuria than observed among patients 
with an onset of type 1 diabetes in adolescence/adulthood. Regarding other risk fac-
tors such as LDL cholesterol, blood pressure and BMI, differences between groups by 
age at onset were small. 
Machine learning output showed that regardless of age at onset and sex several risk 
factors were associated with higher levels of HbA1c such as for instance CVD risk 
factors in terms of increased blood pressure and lipids, BMI, smoking at baseline, ab-
solute age and kidney function. All machine learning models were similar or superior 
to analyses performed with linear regression.
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DISCUSSION
BMI, mortality and reverse causality in patients type 2 diabetes
Some studies have suggested the possibility of an obesity paradox among patients 
with type 2 diabetes(31), with a higher BMI seemingly protective against outcomes, 
or with large spans of minimal mortality risk ranging between overweight to mildly 
obese(52). Our analyses showed J- or U-shaped associations with varying nadirs, as 
high as BMI 35-<40 kg/m2, with respect to mortality and CVD mortality in the short-
term perspective (≤5 years from baseline), whereas long-term follow-up showed that 
the lowest risk was found in the overweight category, indicating that follow-up time 
may play a role in in reverse causality by the exclusion of early deaths(48), and that a 
short follow-up times could potentially contribute to  ndings consistent with an obe-
sity paradox. 
The excess risk of long-term mortality by BMI as well as for CVD mortality was more 
straightforward, displaying a stepwise increase in excess risks among obese patients 
with BMI ≥30 kg/m2 up to a 2-fold risk among patients with BMI ≥40 kg/m2 for out-
comes. Although patients with coexisting conditions such as those with past severe 
CVD events, cancer and dementia were excluded, we found trends towards increased 
excess risks among patients with type 2 diabetes and BMI 20-<25. The previously 
identi ed increased risks of death among patients with BMI <25 kg/m2(32) were like-
wise observed in Study I. It cannot, however, be entirely ruled out that our results 
were in uenced by reverse causality since patients within the normal weight range 
were, for instance, more frequently treated with insulin than patients with higher BMI, 
therefore suggesting the possibility that this group might contain individuals with 
LADA or other subgroups of diabetes(53). 
Further arguments for reverse causality with respect to mortality may be previous data 
which have shown a near linear association between BMI and mortality(35), while in 
the present study we observed attenuated estimates for CVD mortality where patients 
with 20-<25 did not display any signi cant increased risk of CVD mortality compared 
to their matched controls. The very low or non-existent general excess risks of mor-
tality and CVD mortality found in the short-term analyses, may be explained by the 
short duration of diabetes, where patients newly diagnosed receive regular follow-up 
by health care institutions, where CVD risk factors are regularly monitored, while 
the identi cation and management for e.g. hypertension among controls may not be 
optimal(54). 
BMI, weight change, mortality and CVD outcomes including HF in pa-
tients with type 1 diabetes
Type 1 diabetes with intensive insulin therapy is associated with weight gain, how-
ever, the weight trends were similar among patients type 1 diabetes in Study II to 
those observed in the Swedish general population(19), with a relatively normal weight 
pattern. The risks of overweight/obesity on mortality and CVD outcomes including 
HF, were fairly low, although signi cant for death, CVD death and HF. Further on, 
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excessive weight gain seems to predict mortality and HF alike, con rming previous 
research of increased risks of death(45), Even though weight gain has been observed in 
Diabetes Clinical Control and Complications Trial (DCCT)(46, 55), in this present study 
no improved glycemic control was observed among the obese patients, indicating the 
in uence of adverse life style factors could be involved in the acquired weight at base-
line. To improve glycemic control among obese patients with type 1 diabetes there is 
the possibility of bene ts of modern medications such as SGLT-2 inhibitors(56), GLP-1 
receptor(57) agonists or even bariatric surgery, where recent data has identi ed bene ts 
such as reduced risk of CVD and improved glycemic control(58), even though the effect 
from bariatric surgery on blood glucose in type 1 diabetes, has been uncertain in some 
of the previous research(59). Hence, with the relatively small differences with respect 
to BMI and weight change, Study II implicates the importance of life style factors in 
order to avoid obesity but where the concern with respect to weight gain should not 
hinder efforts towards an effective treatment of blood glucose. 
As opposed to Study I, Study II exhibited no increased risks of death among patients 
with normal weight at baseline after taking HbA1c, smoking and follow-up time into 
consideration. Previous research suggested increased risks of mortality in patients 
with BMI <25 kg/m2(60) and an acquired BMI <20 kg/m2. Thus, Study II supports 
recommendations of a healthy life style in patients with type 1 diabetes, including 
maintaining a healthy weight.
Type 2 diabetes, BMI and associations to HF vs atherosclerotic disease
In diabetes type 2, the association between hyperglycemia and atherosclerotic events 
are well established, but the link between obesity and coronary heart disease not as 
extensively investigated. The present study found that, independently of glycemic 
level, the association between BMI and AMI was almost  at, con rming theories 
about two different mechanisms between the outcome of atherosclerotic events and 
incident HF(37). Patients with obesity exhibited an increased risk of HF as previously 
reported(36). The novelty of the  ndings was the excess risk of several times greater 
than for the general population, which was worsened by poor glycemic control. 
There may be several pathways to explain the association between obesity and HF. 
Recent data suggests that increased BMI is associated with increased left ventricu-
lar mass index as well as increased blood pressure(61), suggesting cardiac remodeling 
from a young age independent of glycemic levels, with concurrent high risks of HF in 
obese adolescent men(62). Obesity is also thought to increase the intravascular volume 
via sodium retention where the cardiac output increases in order to maintain a larger 
volume of tissue(37). In addition, obesity in youth was found to increase risk of CKD, 
with a proposed link to glomerular hypertension(63). Our study demonstrates that with 
coexisting obesity and hyperglycemia(37), risks of HF may increase even further. Clini-
cally, Study III underlines the importance of the prevention of HF, perhaps with mod-
ern medication such as SGLT-2 inhibitors where risks have been seen to decrease by 
roughly 30%(64) or with bariatric surgery which has been observed to be an effective 
intervention for reducing obesity related complications(65), for reducing the risk of HF 
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In diabetes type 2, the association between hyperglycemia and atherosclerotic events 
are well established, but the link between obesity and coronary heart disease not as 
extensively investigated. The present study found that, independently of glycemic 
level, the association between BMI and AMI was almost  at, con rming theories 
about two different mechanisms between the outcome of atherosclerotic events and 
incident HF(37). Patients with obesity exhibited an increased risk of HF as previously 
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There may be several pathways to explain the association between obesity and HF. 
Recent data suggests that increased BMI is associated with increased left ventricu-
lar mass index as well as increased blood pressure(61), suggesting cardiac remodeling 
from a young age independent of glycemic levels, with concurrent high risks of HF in 
obese adolescent men(62). Obesity is also thought to increase the intravascular volume 
via sodium retention where the cardiac output increases in order to maintain a larger 
volume of tissue(37). In addition, obesity in youth was found to increase risk of CKD, 
with a proposed link to glomerular hypertension(63). Our study demonstrates that with 
coexisting obesity and hyperglycemia(37), risks of HF may increase even further. Clini-
cally, Study III underlines the importance of the prevention of HF, perhaps with mod-
ern medication such as SGLT-2 inhibitors where risks have been seen to decrease by 
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intervention for reducing obesity related complications(65), for reducing the risk of HF 
in obese individuals(66-68), for improving glycemic control and weight in patients with 
diabetes(69).
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Health management in guidelines
The American diabetes association focuses on the importance of health management 
in both type 1 diabetes and type 2 diabetes particularly with respect to nutritional man-
agement and the avoidance of smoking and overweight/obesity in order to improve 
glycemic levels, blood pressure and lipids, where Studies I-III concordantly support 
these recommendations(70).
Type 1 diabetes and risk factor trajectories by age at onset
High mean values of HbA1c in adolescence/ early adulthood have been identi ed 
among persons with type 1 diabetes(71), in Study IV, patients with an onset of type 1 
diabetes ≤15 years of age displayed similar high means as in the U.S cohort, approxi-
mately 70 mmol/mole. However, patients with an age at onset ≥16 years of age ex-
hibited a gradual increase in HbA1c, while, in contrast, among patients with an age at 
onset <16 years of age, HbA1c declined towards similar mean values i.e, ~65 mmol/
mole from early middle age. The high levels of plasma glucose together with earlier 
onset of albuminuria could potentially contribute to increased excess risks of late 
complications found in previous research in patients with age at onset ≤15 years(50). 
The use of CGM has increased in recent years with an estimated 60% use in 2017, 
based on data from the NDR, while this study ended in 2012. Still, the data we present 
are relevant for many middle-aged and older patients, and also for patients in many 
settings where access to CGM may not be affordable.
Even though we found trajectories for other risk factors such as LDL cholesterol, SBP, 
DBP, eGFR and BMI to be largely independent of age at onset, earlier treatment of 
lipids and blood pressure could potentially be discussed since the accumulation of risk 
factors is an established risk for late complications(43). 
Strengths and limitations
The general strength in Swedish epidemiological research lies in the near nationwide 
coverage of patient cohorts. In this present thesis we had access to large samples of 
Swedish patients with diabetes where the NDR covers roughly ~90% of the Swedish 
population with type 2 diabetes and virtually all patients with type 1 diabetes. In stud-
ies containing matched controls we were able to obtain 5 age- and sex matched con-
trols per patient with diabetes thus generating nearly 1 million controls in Study I and 
Study III. Linking the NDR to the Swedish in-patient registry we received information 
regarding coexisting conditions and outcomes. 
A limitation of the studies on excess risk by BMI compared to the general population 
was the lack of weight data in controls, although excess risk by BMI should be inter-
preted as the excess risk compared to mean BMI in the population, approximately ~26 
kg/m2 in adults (22). Whether diabetes would cancel out the risk conferred by obesity 
in terms of late complications has to be investigated by other means. We also had lim-
ited information on smoking status earlier in life as well as limited information about 
HF diagnoses, where residual confounding and reversed causality may occur, even 
though these studies have considered several important factors. 
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CONCLUSION
For the outcomes of mortality and CVD mortality (Study I) our study suggested that 
factors such as coexisting diseases, smoking and follow-up time may in uence the 
relation between BMI and outcomes. Long-term (≥5 years from baseline) analyses 
showed an increasing risk of death and death from CVD causes from BMI ≥30 kg/m2. 
In Study III, results suggested different mechanisms of pathophysiology between the 
outcome of HF and the outcome of AMI. The association between obesity and HF 
was far greater than for that between obesity and incident AMI, which was seem-
ingly unrelated to BMI. Obesity was however, associated with a multiple-fold risk 
for HF among the severely obese patients (BMI ≥40 kg/m2) compared to age- and 
sex matched controls, further aggravated among patients with poor glycemic control. 
Tentatively, medications targeted towards HF could be considered for patients with 
type 2 diabetes and severe obesity, although this concept would warrant rigorous test-
ing, including randomized controlled trials. Hence, Study I and Study III highlight the 
importance of weight management as an important aspect of diabetes care in order to 
reduce mortality and to reduce the incidence of HF.
In Study II we found that among patients with type 1 diabetes free from prior CVD, 
increasing BMI conferred a modestly elevated risk of mortality, CVD mortality, major 
CVD and HF. For CVD mortality, major CVD and HF we found no suggestion of an 
obesity paradox suggesting increased risk for patients with BMI ≤25 kg/m2, nor did 
we  nd any increased risk of death when factors such as glycemic control, smok-
ing and short follow-up time were taken into consideration. In contrast to previous 
conducted research we did not  nd any evidence of increased risk of mortality or any 
other of the outcomes in the occurrence of weight loss. Thus, our study supports the 
pursuit of life style changes to avoid obesity, but the slightly increased risk of late 
complications among overweight/obese patients should not deter patients and clini-
cians from striving for good glycemic control or intensive insulin therapy.
In Study IV we found that patients with an onset of type 1 diabetes at ≤15 years old 
had increased HbA1c levels in early adulthood, suggesting an increased glycemic 
load over a life time concurrent with an increased probability of albuminuria, with 
the largest differences in mean HbA1c during the  rst decade of adulthood compared 
to patients with an onset of type 1 diabetes ≥16 years. Our study suggests attention 
to the glycemic control in adolescence and early adulthood among patients with an 
early onset and to slow the gradual increase in HbA1c among patients with an onset in 
adolescence or adulthood. High baseline HbA1c coexisted with poor control of other 
CVD risk factors and low education, in support of multifaceted care among patients 
with type 1 diabetes in order to prevent late complications and to increase survival.
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Health management in guidelines
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FUTURE PERSPECTIVES
The ongoing increasing rates of obesity worldwide exhibit future challenges for the 
medical care, where increasing rates of diabetes are to be expected. The research 
presented in this thesis may highlight the possibility that obesity among patients with 
type 1 diabetes and type 2 diabetes may further increase the risk of late complications. 
The largest risk among obese patients with type 2 diabetes may be the substantial 
increased risk of HF, both within the diabetic group and in relation to the general 
population. The data presented in this thesis warrants further research, with focus on 
primary prevention, modern technology and medications that could lessen the risk of 
HF among patients with an onset of type 2 diabetes.  Patients with type 2 diabetes and 
BMI <25 should be further investigated to why this particular group display increased 
risks of mortality, whether this may be mediated by frailty, premature aging, vulner-
ability of particular subgroups of patients with type 2 diabetes or other reasons. 
Regarding obesity among patients with type 1 diabetes, however, in the light of previ-
ous research and Study IV presented in this thesis, there may be more prominent risk 
factors such as HbA1c and kidney function for clinicians to focus on, even though 
maintaining a healthy weight could confer other bene ts such as better quality of life. 
Concurrently Study II also displayed that a healthy weight is probably not associ-
ated with any increased risks for either mortality or CVD complications including 
HF among patients with type 1 diabetes, although more research is needed on the re-
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